{"entity":{"id":"nct05733598","kind":"trial","name":"Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC","aka":[],"tldr":"A phase 2 trial of Bevacizumab, Atezolizumab, Durvalumab in hepatocellular carcinoma, run by Replimune, Inc., now recruiting.","summary":"Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC is a phase 2 interventional study registered as NCT05733598 by Replimune, Inc., with 60 participants planned, started 2024-08-01 and due to reach its primary completion in 2027-12-01. Interventions recorded: RP2, Bevacizumab, Atezolizumab, Durvalumab, RP2 Monotherapy. Conditions listed: Hepatocellular Carcinoma, Biliary Tract Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05733598","url":"https://clinicaltrials.gov/study/NCT05733598"}],"tags":["ctgov-ingest"],"related":[],"cancers":["hcc"],"sections":[],"technologies":[],"targets":[],"drugs":["bevacizumab","atezolizumab","durvalumab"],"companies":["replimune"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05733598","phase":"2","setting":"A Phase 2, Open-label, Multicenter Study Investigating RP2 Oncolytic Immunotherapy in Combination With Second-line Therapy in Patients With Locally Advanced Unresectable, Recurrent and/or Metastatic Hepatocellular Carcinoma","sponsor":"Replimune, Inc.","enrolled":60,"outcomes":[]},"route":"/trials/nct05733598/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"}],"company":[{"id":"replimune","kind":"company","name":"Replimune","route":"/companies/replimune/"}]}}